Merck & Co Inc
MRK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Merck & Co Inc News & Analysis
stocks
A wave of US biotech IPOs may be starting - here’s why
M&A activity is bolstering IPOs within key areas of the biotech space. A GLP-1 maker and a protein biomarker detection company are the latest.
markets
Market Minute: Trade policy dominates, opportunities in global healthcare, and a local rate cut on the cards
Senior Portfolio Manager Bryce Anderson reviews the biggest market movements of the week, with Trump’s trade policy dominating again.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,260.90 | 40.40 | 0.44% |
| CAC 40 | 8,301.85 | 32.65 | -0.39% |
| DAX 40 | 25,970.11 | 288.00 | -1.10% |
| Dow JONES (US) | 52,766.88 | 419.02 | -0.79% |
| FTSE 100 | 10,789.28 | 34.98 | -0.32% |
| HKSE | 25,329.73 | 237.26 | -0.93% |
| NASDAQ | 26,099.77 | 271.12 | -1.03% |
| Nikkei 225 | 66,215.34 | 96.59 | -0.15% |
| NZX 50 Index | 13,786.90 | 130.40 | -0.94% |
| S&P 500 | 7,631.47 | 54.67 | -0.71% |
| S&P/ASX 200 | 9,066.70 | 41.70 | 0.46% |
| SSE Composite Index | 3,979.89 | 6.41 | -0.16% |